Researchers have shown that a simple blood test for plasma p-tau181 can flag subjective cognitive decline, an early but biologically distinct stage in Alzheimer’s, years before traditional symptoms appear.
Study: Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease. Image Credit: Belight / Shutterstock
In a recent study published in the journal Molecular Psychiatry, a group of researchers evaluated whether blood biomarkers can distinguish subjective cognitive decline (SCD) as a distinct transitional stage in Alzheimer’s disease (AD) progression.
Background
What if a simple blood test could detect AD years before symptoms appear? AD begins long before memory loss, progressing silently through…